These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 31613384)

  • 1. The interactions of dopamine and oxidative damage in the striatum of patients with neurodegenerative diseases.
    Li H; Yang P; Knight W; Guo Y; Perlmutter JS; Benzinger TLS; Morris JC; Xu J
    J Neurochem; 2020 Jan; 152(2):235-251. PubMed ID: 31613384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microglia Implicated in Tauopathy in the Striatum of Neurodegenerative Disease Patients from Genotype to Phenotype.
    Li H; Knight WC; Yang P; Guo Y; Perlmutter JS; Morris JC; Bateman RJ; Benzinger TLS; Xu J
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32842621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Damage to dopamine systems differs between Parkinson's disease and Alzheimer's disease with parkinsonism.
    Murray AM; Weihmueller FB; Marshall JF; Hurtig HI; Gottleib GL; Joyce JN
    Ann Neurol; 1995 Mar; 37(3):300-12. PubMed ID: 7695230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution.
    Piggott MA; Marshall EF; Thomas N; Lloyd S; Court JA; Jaros E; Burn D; Johnson M; Perry RH; McKeith IG; Ballard C; Perry EK
    Brain; 1999 Aug; 122 ( Pt 8)():1449-68. PubMed ID: 10430831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dopaminergic activities in the human striatum: rostrocaudal gradients of uptake sites and of D1 and D2 but not of D3 receptor binding or dopamine.
    Piggott MA; Marshall EF; Thomas N; Lloyd S; Court JA; Jaros E; Costa D; Perry RH; Perry EK
    Neuroscience; 1999 May; 90(2):433-45. PubMed ID: 10215149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nicotine binding in human striatum: elevation in schizophrenia and reductions in dementia with Lewy bodies, Parkinson's disease and Alzheimer's disease and in relation to neuroleptic medication.
    Court JA; Piggott MA; Lloyd S; Cookson N; Ballard CG; McKeith IG; Perry RH; Perry EK
    Neuroscience; 2000; 98(1):79-87. PubMed ID: 10858614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoamine vesicular uptake sites in patients with Parkinson's disease and Alzheimer's disease, as measured by tritiated dihydrotetrabenazine autoradiography.
    Lehéricy S; Brandel JP; Hirsch EC; Anglade P; Villares J; Scherman D; Duyckaerts C; Javoy-Agid F; Agid Y
    Brain Res; 1994 Oct; 659(1-2):1-9. PubMed ID: 7820649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective increase of NMDA-sensitive glutamate binding in the striatum of Parkinson's disease, Alzheimer's disease, and mixed Parkinson's disease/Alzheimer's disease patients: an autoradiographic study.
    Ułas J; Weihmuller FB; Brunner LC; Joyce JN; Marshall JF; Cotman CW
    J Neurosci; 1994 Nov; 14(11 Pt 1):6317-24. PubMed ID: 7965038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuropathological correlates of dopaminergic imaging in Alzheimer's disease and Lewy body dementias.
    Colloby SJ; McParland S; O'Brien JT; Attems J
    Brain; 2012 Sep; 135(Pt 9):2798-808. PubMed ID: 22961551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of dopamine D₃ receptor in the striatal regions and substantia nigra in diffuse Lewy body disease.
    Sun J; Cairns NJ; Perlmutter JS; Mach RH; Xu J
    Neuroscience; 2013 Sep; 248():112-26. PubMed ID: 23732230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential modification of dopamine transporter and tyrosine hydroxylase mRNAs in midbrain of subjects with Parkinson's, Alzheimer's with parkinsonism, and Alzheimer's disease.
    Joyce JN; Smutzer G; Whitty CJ; Myers A; Bannon MJ
    Mov Disord; 1997 Nov; 12(6):885-97. PubMed ID: 9399211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Substantia nigra Marinesco bodies are associated with decreased striatal expression of dopaminergic markers.
    Beach TG; Walker DG; Sue LI; Newell A; Adler CC; Joyce JN
    J Neuropathol Exp Neurol; 2004 Apr; 63(4):329-37. PubMed ID: 15099023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interplay of Ferritin Accumulation and Ferroportin Loss in Ageing Brain: Implication for Protein Aggregation in Down Syndrome Dementia, Alzheimer's, and Parkinson's Diseases.
    Raha AA; Biswas A; Henderson J; Chakraborty S; Holland A; Friedland RP; Mukaetova-Ladinska E; Zaman S; Raha-Chowdhury R
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35162984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biochemistry of postmortem brains in Parkinson's disease: historical overview and future prospects.
    Nagatsu T; Sawada M
    J Neural Transm Suppl; 2007; (72):113-20. PubMed ID: 17982884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reprint of: revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse.
    Perfeito R; Cunha-Oliveira T; Rego AC
    Free Radic Biol Med; 2013 Sep; 62():186-201. PubMed ID: 23743292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Semichronic inhibition of glutathione reductase promotes oxidative damage to proteins and induces both transcription and translation of tyrosine hydroxylase in the nigrostriatal system.
    Romero-Ramos M; Venero JL; Garcia-Rodriguez S; Ayala A; Machado A; Cano J
    Free Radic Res; 2003 Sep; 37(9):1003-12. PubMed ID: 14670008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system.
    Kirik D; Rosenblad C; Burger C; Lundberg C; Johansen TE; Muzyczka N; Mandel RJ; Björklund A
    J Neurosci; 2002 Apr; 22(7):2780-91. PubMed ID: 11923443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Axonal damage and loss of connectivity in nigrostriatal and mesolimbic dopamine pathways in early Parkinson's disease.
    Caminiti SP; Presotto L; Baroncini D; Garibotto V; Moresco RM; Gianolli L; Volonté MA; Antonini A; Perani D
    Neuroimage Clin; 2017; 14():734-740. PubMed ID: 28409113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiotensin II receptor binding associated with nigrostriatal dopaminergic neurons in human basal ganglia.
    Allen AM; MacGregor DP; Chai SY; Donnan GA; Kaczmarczyk S; Richardson K; Kalnins R; Ireton J; Mendelsohn FA
    Ann Neurol; 1992 Sep; 32(3):339-44. PubMed ID: 1416803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does loss of nerve growth factor receptors precede loss of cholinergic neurons in Alzheimer's disease? An autoradiographic study in the human striatum and basal forebrain.
    Strada O; Hirsch EC; Javoy-Agid F; Lehéricy S; Ruberg M; Hauw JJ; Agid Y
    J Neurosci; 1992 Dec; 12(12):4766-74. PubMed ID: 1464766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.